VERA - Vera Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
VERA price evolution
VERA
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $172.02 | $171.6 | $190.61 | $204.45 |
| Long term investments | ||||
| Property, plant & equipment | $2.95 | $3.5 | $4.07 | $4.64 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $175.55 | $175.6 | $195.18 | $209.6 |
| Current liabilities | ||||
| Accounts payable | $11.12 | $12.3 | $13.28 | $5.33 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $22.3 | $24.6 | $26.84 | $23.53 |
| Long term debt | $49.88 | $25 | $24.96 | $24.89 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $73.86 | $51.9 | $54.66 | $51.9 |
| Shareholders' equity | ||||
| Retained earnings | -$309.1 | -$283.4 | -$263.34 | -$243.18 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $53.7 | |||
| Short term investments | ||||
| Net receivables | $0.05 | |||
| Inventory | ||||
| Total current assets | $172.02 | $125.7 | $82.54 | $54.26 |
| Long term investments | ||||
| Property, plant & equipment | $2.95 | $5.22 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.29 | |||
| Total investments | ||||
| Total assets | $175.55 | $131.44 | $83.75 | $54.55 |
| Current liabilities | ||||
| Accounts payable | $11.12 | $11.99 | $1.39 | $0.91 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $22.3 | $25.6 | $7.69 | $2.41 |
| Long term debt | $49.88 | $24.81 | $4.92 | |
| Total noncurrent liabilities | $1.92 | |||
| Total debt | ||||
| Total liabilities | $73.86 | $54.53 | $14.16 | $4.33 |
| Shareholders' equity | ||||
| Retained earnings | -$309.1 | -$213.11 | -$124.06 | -$91.45 |
| Other shareholder equity | $139.58 | |||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $25.24 | $15.06 | $17.02 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.42 | $0.14 | -$0.09 | |
| Net income | ||||
| Net income | -$24.68 | -$14.85 | -$17.09 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 30 Jan 2013 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $15.32 | |||
| Cost of revenue | ||||
| Gross Profit | $9 | |||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $52.24 | $11.96 | $8.6 | |
| Operating income | -$52.24 | -$11.96 | $0.72 | |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0 | -$0 | $0.01 | |
| Interest expense | $0.17 | $0.05 | ||
| Net income | ||||
| Net income | -$53.41 | -$11.85 | $0.74 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$83.99 | -$81.55 | -$39.45 | -$4.2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $81.22 | $80.32 | $80.27 | $53.88 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$49.2 | -$29.25 | $31.84 | $25.97 |
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 30 Jan 2013 |
|---|---|---|---|---|
| Net income | -$53.41 | -$11.85 | $0.74 | |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$34.81 | -$10.29 | $1.5 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$4.2 | -$0.04 | -$0.13 | -$0.94 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $53.88 | $85.29 | -$0.14 | -$0.05 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $25.97 | $50.44 | -$10.55 | $0.52 |
News
Fundamentals
| Market cap | $1.84B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 44.43M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 7.71 |
| Quick ratio | N/A |